Mexico’s Largest Optical Retailer to Use DIAGNOS’ AI Technology to Detect Early Stage Blindness
07 October 2020 - 1:00AM
Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
issues using advanced Artificial Intelligence (AI), announces a
contract with Devlyn Grupo (“Devlyn”), an important optical
retailer with over nine hundred stores in Mexico and Guatemala.
Devlyn will be testing CARA AI technology for diabetic retinopathy
screening at select optical retail locations. A roll out to more
stores may happen in early 2021 if testing is conclusive.
“I am pleased to announce our collaboration with
DIAGNOS. Devlyn, which has a long-lasting tradition in optical and
clinical eye care, offers the very best of vision care, while
adhering to strict safety protocols during the pandemic.
Digitalization, telemedicine and accurate clinical eye tests from
DIAGNOS’ CARA AI platform supports our mission”, said
Melanie Devlyn, CEO of Devlyn.
André Larente, President of
DIAGNOS, added: “DIAGNOS is proud to join Devlyn’s
well-known reputation of optical and clinical eye care services.
We’re determined to strongly enhance Devlyn’s great work
contribution in the world of vision health with our advanced and
flexible real-time AI solution for the prevention and avoidance of
vision-threatening diseases”.
DIAGNOS is also announcing a correction to its
press release of September 28, 2020 (the “Press Release”). The
Press Release mentions that Mr. Vincent Duhamel is Vice Chairman of
Fiera Capital’s board of directors. However, Mr. Duhamel has ceased
to be Vice Chairman of Fiera Capital’s board of directors as of
June 30, 2020. This correction does not change any other
information reported in the Press Release.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and ww.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024